期刊文献+

肾性继发性甲状旁腺功能亢进的内科治疗研究进展 被引量:3

Research Progress on Medical Treatment of Renal Secondary Hyperparathyroidism
下载PDF
导出
摘要 继发性甲状旁腺功能亢进(SHPT)是慢性肾脏病矿物质及骨代谢异常中最常见的临床表现,大大增加了慢性肾脏病患者心血管事件的发生率及死亡率,所以关于SHPT治疗方面的研究一直都是慢性肾脏病领域的热点。目前SHPT的治疗主要包括内科治疗、外科手术治疗和介入治疗。本文将对SHPT的内科治疗措施进行综述,为SHPT患者选择有效的治疗方案。 Secondary hyperparathyroidism(SHPT) is the most common clinical manifestation of mineral and bone metabolism abnormalities in chronic kidney disease, which greatly increases the incidence and mortality of cardiovascular events in patients with chronic kidney disease, so about SHPT Treatment research has always been a hot spot in the field of chronic kidney disease. The current treatment of SHPT mainly includes medical treatment, surgical treatment and interventional treatment. This article will review the medical treatment measures of SHPT and select effective treatment options for clinicians for SHPT patients.
作者 刘慧敏 李长红 Li Huimin;Li Changhong(The First Affiliated Hospital of Jiamusi University,Jiamusi 154002,China)
出处 《广东化工》 CAS 2020年第23期71-72,共2页 Guangdong Chemical Industry
关键词 继发性甲状旁腺功能亢进 磷结合剂 活性维生素D及类似物 钙敏感受体激动剂 血液透析 secondary hyperparathyroidism phosphorus binder active vitamin d and analogues calcium sensitive receptor agonists Hemodialysis
  • 相关文献

参考文献8

二级参考文献75

  • 1燕宇.西那卡塞的临床应用以及研究进展[J].中国血液净化,2012,11(8):460-463. 被引量:23
  • 2杨国刚.慢性肾功能衰竭患者高磷血症研究及治疗进展[J].吉林医药学院学报,2010,31(2):102-105. 被引量:13
  • 3王笑云,谭若芸.慢性肾脏病(CKD)继发性甲状旁腺功能亢进的近代治疗[J].中国血液净化,2005,4(1):1-4. 被引量:20
  • 4Wallot M, Bonzel K E, Winter A, et al. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients [J]. Pediatr Nephrol , 2011, 10(5): 625.
  • 5Goodman W G. Importance of hyperphosphataemia in the cardio - renalaxis [J]. Nephrol Dial Transplant, 2004, 19 (Suppl 1): 14.
  • 6Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis [J]. Nephrol Dial Transplant, 2009, 24 (1): 278.
  • 7Achinger S G, Ayus J C. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk Iactor[J]. J Am Soc Nephrol, 2006, 17(3): 255.
  • 8D Almeida Filho E J, Da Cruz E A, Hoette M, et al. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients[J]. Sao Paulo Med J, 2009, 118(6): 179.
  • 9LezaicV, Tirmenstajn r Iankovic B, Bukvic D, etal. Efficacy of hyperphosp hatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification [J]. Clin Nephml, 2009, 71 (1): 21.
  • 10KENDRICKJ, CHONCHOLM. The role of phosphorus in the development and progression of vascular calcification[ J ]. Am J Kidney Dis, 2011, 58(5): 826-834.

共引文献110

同被引文献21

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部